Generation of a syngeneic mouse model to study the intraperitoneal dissemination of ovarian cancer with in vivo luciferase imaging
Generation of a syngeneic mouse model to study the intraperitoneal dissemination of ovarian cancer with in vivo luciferase imaging
复制标题
DOI：
10.1002/bio.1112
复制
发表时间：
2009-09-01
期刊：
影响因子：
2.9
通讯作者：
Yaegashi, Nobuo
中科院分区：
文献类型：
--
作者：
Toyoshima, Masafumi;Tanaka, Yoshinori;Yaegashi, Nobuo
为了促进在生理条件下发现和研究抗癌疗法，我们在小鼠中设计了卵巢癌细胞系HM-1/luc。该细胞稳定地表达萤火虫荧光素酶，并产生可以使用体内成像系统（IVIS）检测到的光。亲本HM-1细胞对B6 C3 F1小鼠引起严重的癌性腹膜炎，但对C57 BL 6小鼠不引起。已建立的HM-1/luc细胞表现出与HM-1细胞相似的病理学结果。将HM-1/luc细胞注射到B6 C3 F1小鼠的腹腔中，并且在接种后每周进行IVIS 2000以监测腹膜内肿瘤生长。将小鼠分为三组：非CDDP治疗组（对照组）和CDDP治疗组（0.2和0.4 mg）。CDDP的疾病抑制作用通过CDDP处理的小鼠的显著延长的存活（对照23 +/-1.9天，CDDP 0.2mg 29.6 +/-2.9天; p < 0.05）反映;总光子和通量面积降低。腹腔内肿瘤的光学成像通过在体生物发光是有效的无创监测和半定量分析。我们的同基因小鼠模型具有卵巢癌的相关临床特征，这使其成为开发新的卵巢癌疗法的有用模型。版权所有（C）2009约翰威利父子有限公司
In order to facilitate the discovery and investigation of anti-cancer therapeutics under physiological conditions, we have engineered the ovarian cancer cell line, HM-1/luc, in mice. This cell stably expresses firefly luciferase and produces light that can be detected using an in vivo imaging system (IVIS). Parental HM-1 cells cause severe carcinomatous peritonitis to B6C3F1 mice, but not to C57BL6 mice. Established HM-1/luc cells showed pathologically similar findings to HM-1 cells. HM-1/luc cells were injected into the peritoneal cavity of B6C3F1 mice and IVIS 2000 was conducted weekly after inoculation to monitor intraperitoneal tumor growth. The mice were divided into three groups: non-CDDP-treated (control) and CDDP-treated (0.2 and 0.4 mg). A disease-suppressive effect of the CDDP was reflected by the significantly prolonged survival of the CDDP-treated mice (control 23 +/- 1.9 days, CDDP 0.2 mg 29.6 +/- 2.9 days; p < 0.05); the total photon and area of flux were decreased. The optical imaging of intraperitoneal tumors via in vivo bioluminescence is effective for noninvasive monitoring and semi-quantitative analysis. Our syngeneic mouse model has the relevant clinical features of ovarian cancer, which makes it a useful model for developing new ovarian cancer therapies. Copyright (C) 2009 John Wiley & Sons, Ltd.